Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

16.04 +0.29 (+1.87%)
Streaming Delayed Price Updated: 1:34 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,200,351
Open 15.71
Bid (Size) 16.03 (26)
Ask (Size) 16.04 (23)
Prev. Close 15.74
Today's Range 15.52 - 16.25
52wk Range 7.085 - 16.13
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript
TEVA earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed... 
Via Benzinga

Performance

YTD
+50.28%
+50.28%
1 Month
+12.92%
+12.92%
3 Month
+32.08%
+32.08%
6 Month
+75.25%
+75.25%
1 Year
+76.21%
+76.21%

More News

Read More
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
TEVA Stock Earnings: Teva Pharmaceutical Indus Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
Via Investor's Business Daily
Wall Street Poised For Muted Open On Mixed Earnings, With More Fed Speeches In Store: Analyst Sees S&P 500 Crossing Late-March High
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
From Teva Pharmaceutical Industries Limited
Via Business Wire
Investor Sentiment Falls Further, Dow Gains For Fifth Session
Via Benzinga
Topics Stocks
Exposures US Equities
Uber, Lyft And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Via Benzinga
Topics Stocks
Exposures US Equities
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
Via Investor's Business Daily
Teva to Present at the 2024 Bank of America Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Update: Israeli Stocks On U.S. Exchanges Have Outpaced Nasdaq And S&P 500 Since October 7/23
Via Talk Markets
Topics Stocks
Exposures US Equities
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.